Patient characteristics (N = 26 695)
| Variables . | Data . |
|---|---|
| Sex | |
| Female | 11 113 (41.6) |
| Male | 15 578 (58.3) |
| Age, y | |
| Median | 45 |
| Range | 16-69 |
| PS | |
| 0-1 | 21 567 (80.8) |
| ≥2 | 1 638 (6.1) |
| Missing | 3 490 (13.1) |
| HCT-CI | |
| ≤2 | 14 906 (55.8) |
| ≥3 | 2 275 (8.5) |
| Missing | 9 514 (35.7) |
| Disease | |
| AML/MDS | 13 613 (51.0) |
| ALL | 5 129 (19.2) |
| ATL | 1 153 (4.3) |
| CML | 2 141 (8.0) |
| NHL | 2 218 (8.3) |
| AA | 1 024 (3.9) |
| Other | 1 417 (5.3) |
| Disease risk | |
| Standard | 14 088 (52.7) |
| High | 12 607 (47.2) |
| Pretransplant therapy period, mo | |
| Median | 8.2 |
| Range | 1.2-779.3 |
| Donor source | |
| Rel-BM | 4 899 (18.4) |
| Rel-PB | 5 389 (20.2) |
| UR-BM | 10 801 (40.5) |
| UR-CB | 5 425 (20.3) |
| HLA mismatch | |
| No | 13 969 (52.3) |
| Yes | 12 726 (47.7) |
| Sex mismatch | |
| No | 13 136 (49.2) |
| M to F | 5 729 (21.4) |
| F to M | 5 657 (21.1) |
| ABO mismatch | |
| No | 12 060 (45.1) |
| Minor | 5 169 (19.3) |
| Major | 4 694 (17.5) |
| Both | 2 408 (9.0) |
| Conditioning regimens | |
| MAC | 16 480 (61.7) |
| RIC | 8 277 (31.0) |
| GVHD prophylaxis | |
| CyA based | 12 612 (47.2) |
| Tac based | 14 083 (52.8) |
| Follow-up period, mo | |
| Median | 58.7 |
| Range | 1.4-306.6 |
| Transplant year | |
| 2008 or before | 12 495 (46.8) |
| 2009 or later | 14 200 (53.2) |
| Variables . | Data . |
|---|---|
| Sex | |
| Female | 11 113 (41.6) |
| Male | 15 578 (58.3) |
| Age, y | |
| Median | 45 |
| Range | 16-69 |
| PS | |
| 0-1 | 21 567 (80.8) |
| ≥2 | 1 638 (6.1) |
| Missing | 3 490 (13.1) |
| HCT-CI | |
| ≤2 | 14 906 (55.8) |
| ≥3 | 2 275 (8.5) |
| Missing | 9 514 (35.7) |
| Disease | |
| AML/MDS | 13 613 (51.0) |
| ALL | 5 129 (19.2) |
| ATL | 1 153 (4.3) |
| CML | 2 141 (8.0) |
| NHL | 2 218 (8.3) |
| AA | 1 024 (3.9) |
| Other | 1 417 (5.3) |
| Disease risk | |
| Standard | 14 088 (52.7) |
| High | 12 607 (47.2) |
| Pretransplant therapy period, mo | |
| Median | 8.2 |
| Range | 1.2-779.3 |
| Donor source | |
| Rel-BM | 4 899 (18.4) |
| Rel-PB | 5 389 (20.2) |
| UR-BM | 10 801 (40.5) |
| UR-CB | 5 425 (20.3) |
| HLA mismatch | |
| No | 13 969 (52.3) |
| Yes | 12 726 (47.7) |
| Sex mismatch | |
| No | 13 136 (49.2) |
| M to F | 5 729 (21.4) |
| F to M | 5 657 (21.1) |
| ABO mismatch | |
| No | 12 060 (45.1) |
| Minor | 5 169 (19.3) |
| Major | 4 694 (17.5) |
| Both | 2 408 (9.0) |
| Conditioning regimens | |
| MAC | 16 480 (61.7) |
| RIC | 8 277 (31.0) |
| GVHD prophylaxis | |
| CyA based | 12 612 (47.2) |
| Tac based | 14 083 (52.8) |
| Follow-up period, mo | |
| Median | 58.7 |
| Range | 1.4-306.6 |
| Transplant year | |
| 2008 or before | 12 495 (46.8) |
| 2009 or later | 14 200 (53.2) |
Unless otherwise indicated, data are n (%).
AA, aplastic anemia; ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; ATL, adult T-cell lymphoma/leukemia; CML, chronic myelogenous leukemia; CyA, cyclosporine; F, female; GVHD, graft-versus-host disease; M, male; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma; Rel-BM, bone marrow from relative; Rel-PB, peripheral blood stem cells from relative; RIC, reduced-intensity conditioning; Tac, tacrolimus; UR-BM, bone marrow from unrelated donor; UR-CB, cord blood from unrelated donor.